Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ATBPFNASDAQ:MURANASDAQ:NBRVNYSE:OSTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATBPFAntibe Therapeutics$0.22$0.22$0.11▼$0.89$11.42M0.5127,352 shsN/AMURAMural Oncology$2.62-0.8%$2.17$0.95▼$4.74$45.25M3.911.31 million shs33,956 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/AOSTXOS Therapies$1.53-3.2%$1.62$1.12▼$7.00$42.99MN/A469,716 shs93,072 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATBPFAntibe Therapeutics0.00%0.00%0.00%0.00%-0.19%MURAMural Oncology0.00%-4.73%+0.38%-28.80%-21.79%NBRVNabriva Therapeutics0.00%0.00%0.00%+4,900.00%+4,900.00%OSTXOS Therapies0.00%-8.93%-20.73%-7.27%+152,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATBPFAntibe TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMURAMural Oncology3.2452 of 5 stars3.35.00.00.02.41.71.3NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOSTXOS Therapies1.7854 of 5 stars3.70.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATBPFAntibe Therapeutics 0.00N/AN/AN/AMURAMural Oncology 2.60Moderate Buy$13.00396.18% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/AOSTXOS Therapies 3.40Buy$18.001,076.47% UpsideCurrent Analyst Ratings BreakdownLatest ATBPF, MURA, NBRV, and OSTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/22/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/7/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/2/2025OSTXOS TherapiesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.003/31/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/26/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/25/2025MURAMural OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight3/25/2025MURAMural OncologyRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$18.003/25/2025MURAMural OncologyJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/12/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATBPFAntibe TherapeuticsN/AN/AN/AN/A$0.58 per shareN/AMURAMural OncologyN/AN/AN/AN/A$15.81 per shareN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00OSTXOS TherapiesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATBPFAntibe Therapeutics-$14.73M-$0.25N/A∞N/AN/A-56.48%-29.07%N/AMURAMural Oncology-$207.45M-$7.67N/AN/AN/AN/A-70.10%-61.30%8/12/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/AOSTXOS Therapies-$7.79M-$0.86N/AN/AN/AN/AN/A-569.57%N/ALatest ATBPF, MURA, NBRV, and OSTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MURAMural Oncology-$2.12-$1.93+$0.19-$1.93N/AN/A3/11/2025Q4MURAMural Oncology-$1.96-$2.01-$0.05-$2.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATBPFAntibe TherapeuticsN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATBPFAntibe TherapeuticsN/A10.0610.06MURAMural OncologyN/A7.387.38NBRVNabriva Therapeutics0.120.850.52OSTXOS TherapiesN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATBPFAntibe TherapeuticsN/AMURAMural Oncology80.21%NBRVNabriva Therapeutics0.27%OSTXOS TherapiesN/AInsider OwnershipCompanyInsider OwnershipATBPFAntibe Therapeutics9.00%MURAMural Oncology0.06%NBRVNabriva Therapeutics1.63%OSTXOS Therapies13.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATBPFAntibe Therapeutics1152.98 million48.24 millionNot OptionableMURAMural Oncology11917.27 million17.01 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableOSTXOS TherapiesN/A28.10 millionN/AN/AATBPF, MURA, NBRV, and OSTX HeadlinesRecent News About These CompaniesBuy Rating for OS Therapies: Promising Developments and Strategic Positioning in Cancer ImmunotherapyMay 21, 2025 | tipranks.comOS Therapies Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | businesswire.comOS Therapies Launches Subsidiary To Commercialize Canine Osteosarcoma TreatmentMay 16, 2025 | finanzen.atOS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine OsteosarcomaMay 15, 2025 | finance.yahoo.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Shalom Auerbach Sells 82,000 SharesMay 10, 2025 | insidertrades.comOS Therapies Inc sees $163,918 in stock sales by major shareholderMay 9, 2025 | investing.comOS Therapies secures patent for cancer immunotherapy techMay 9, 2025 | investing.comEmmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer TherapiesMay 2, 2025 | businesswire.comOS Therapies granted FDA meeting for OST-HER2April 22, 2025 | markets.businessinsider.comOS Therapies FDA Meeting Request GrantedApril 22, 2025 | businesswire.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $67,516.20 in StockApril 12, 2025 | insidertrades.comOS Therapies Announces Positive Data From The Study Of OST-HER2 In Osteosarcoma In DogsApril 12, 2025 | nasdaq.comOS Therapies Inc: Shalom Auerbach sells $81,566 in common stockApril 11, 2025 | investing.comOS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in HumansApril 10, 2025 | businesswire.comOS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in HumansApril 10, 2025 | newsfilecorp.comOS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in HumansApril 10, 2025 | newsfilecorp.comOS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala PharmaceuticalsApril 9, 2025 | businesswire.comLake Street Initiates Coverage of OS Therapies (OSTX) with Buy RecommendationApril 3, 2025 | msn.comOS Therapies Inc Reports 2024 Net Loss Per Share of $0. ...April 1, 2025 | gurufocus.comOS Therapies Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATBPF, MURA, NBRV, and OSTX Company DescriptionsAntibe Therapeutics OTCMKTS:ATBPF$0.22 0.00 (0.00%) As of 04/16/2025Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Mural Oncology NASDAQ:MURA$2.62 -0.02 (-0.76%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.68 +0.06 (+2.14%) As of 05/30/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.OS Therapies NYSE:OSTX$1.53 -0.05 (-3.16%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.53 0.00 (0.00%) As of 05/30/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
